English (UK)
中文版
INOVOTION 
CRO Preclinical
In vivo efficacy evaluation in oncology
In vivo efficacy evaluation in oncology
Mr. Philippe Fornies
Head of Business DevelopmentInsilico Medicine US Inc 
Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trial outcomes.
Dr. Qingsong Zhu
COOINTERVENN BIOSCIENCES
Venn Biosciences innovates cancer diagnostics using Artificial Intelligence (AI) and next-gen mass spectrometry, unlocking glycoproteomics for Biomarker and Target Discovery.
Mr. FADZ JABAR
VICE PRESIDENT, BUSINESS DEVELOPMENTiX Biopharma Ltd 
iX Biopharma is established in 2008, and listed on Singapore Stock Exchange (Catalist Board) in 2015. iX is a specialist in novel wafer formulations using patented sublingual delivery technology, WaferiXTM , which is patented in China to 2033. R&D and manufacturing at wholly-owned GMP licensed facility in Melbourne, Australia.
Yuhuan Wang
Senior BD Manager
Jemincare 
Jemincare is a leading pharmaceutical group in China with $5.2B revenue in 2019. JeminCare is dedicated to providing novel healthcare solutions with Rx and OTC drugs with strategic fields in renal disease, oncology, cardiovascular, anti-infection, respiratory, and analgesic. We have a well-established marketing and sales network in China with a team of more than 5000 sales reps.
Located in Shanghai, Jemincare R&D center has 400+ experienced scientists and more than 30 novel prescription drugs in the pipeline.
Mrs. Lilian Peng
BD ManagerJiangsu Hengrui Medicine Co.,Ltd.
Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Ms. Linda Zhao
Head, US BD TeamJiangsu Hengrui Pharma
Hengrui is the largest pharmaceutical company based in China by market cap (around 90 billion USD) and among the top ones by revenue and R&D spending (3.28b USD and 549m USD in 2019, respectively). 5+ differentiated products in global clinical development with commercial rights available for discussions.
Responsive Web Design powered by 